• Case-Based Roundtable
  • General Dermatology
  • Eczema
  • Chronic Hand Eczema
  • Alopecia
  • Aesthetics
  • Vitiligo
  • COVID-19
  • Actinic Keratosis
  • Precision Medicine and Biologics
  • Rare Disease
  • Wound Care
  • Rosacea
  • Psoriasis
  • Psoriatic Arthritis
  • Atopic Dermatitis
  • Melasma
  • NP and PA
  • Skin Cancer
  • Hidradenitis Suppurativa
  • Drug Watch
  • Pigmentary Disorders
  • Acne
  • Pediatric Dermatology
  • Practice Management
  • Prurigo Nodularis
  • Buy-and-Bill

Opinion

Video

Comprehensive Analysis: Upa Outshines Dupi Across Key Measures

Author(s):

Raj Chovatiya, MD, PhD, MSCI,Christopher G. Bunick, MD, PhD

Dermatology experts analyze the superior outcomes of upadacitinib compared with dupilumab across key efficacy measures in atopic dermatitis treatment.

Related Videos
1 KOL is featured in this series.
1 KOL is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 expert is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
1 KOL is featured in this series.
Related Content
Experts Delve Into Upadacitinib vs Dupilumab: Insights From LEVEL UP
October 9th 2024

Experts Delve Into Upadacitinib vs Dupilumab: Insights From LEVEL UP

The Cutaneous Connection: Episode 1- Cannabinoid Use in Dermatology
June 25th 2020

The Cutaneous Connection: Episode 1- Cannabinoid Use in Dermatology

Reviewing New Tapinarof Data for Atopic Dermatitis Treatment
December 20th 2023

Reviewing New Tapinarof Data for Atopic Dermatitis Treatment

Phase 2 Trial of ADX-629 Underway for Treatment of AD
April 10th 2023

Phase 2 Trial of ADX-629 Underway for Treatment of AD

Christoph R. Loeser, MD, IFAAD
March 14th 2023

Dermatologist Shares Insights on Saving the Nail at Annual Meeting

Considering and Improving Patient Quality of Life in Dermatologic Conditions
March 10th 2023

Considering and Improving Patient Quality of Life in Dermatologic Conditions

© 2024 MJH Life Sciences

All rights reserved.